Literatur
- 1
Tukiainen P, Taskinen E, Holsti P, Korhola O, Valle M.
Prognosis of cryptogenic fibrosing alveolitis.
Thorax.
1983;
38
349-355
- 2
Coultas D B, Zumwalt R E, Black W C, Sobonya R E.
The epidemiology of interstitial lung diseases.
Am J Respir Crit Care Med.
1994;
150
967-972
- 3
Turner-Warwick M, Burrows B E, Johnson A.
Cryptogenic fibrosing alveolitis: clinical features and their influence on survival.
Thorax.
1980;
35
593-599
- 4
Majumdar S, Li D, Ansari T, Pantelidis P, Black C M, Gizycki M, du Bois R M, Jeffery P K.
Tissue cytokine profiles of cryptogenic fibrosing alveolitis (CFA) and fibrosing alveolitis
associated with systemic sclerosis (FASSc) are distinct: a quantitative in situ study
of open lung biopsies.
Eur Respir J.
1999;
14
251-257
- 5
Elias A D.
Salvage therapy for soft tissue sarcomas.
Semin Oncol.
1994;
21
S7: 76-81
- 6
Barth A, Morton D L.
The role of adjuvant therapy in melanoma management.
Cancer.
1995;
75
726-734
- 7
Windbichler G H, Hausmaninger H, Stummvoll W, Graf A H, Kainz C, Lahodny J, Denison U,
Muller Holzner E, Marth C.
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III
trial.
Br J Cancer.
2000;
82
1138-1144
- 8
Gurujeyalakshmi G, Giri S N.
Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse
model of lung fibrosis: Downregulation of TGF-β and procollagen I and III gene expression.
Exp Lung Res.
1995;
21
791-808
- 9
Ziesche R, Kink E, Herold C, Podolsky A, Block L H.
Therapy of chronic interstitial lung disease with a combination of Interferon gamma
and low-dose prednisolone.
Chest.
1996;
110
25S
- 10
Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block L H.
A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone
in patients with idiopathic pulmonary fibrosis.
N Engl J Med.
1999;
314
1264-1269
1 Herrn Prof. Dr. med. Heinrich Matthys zum 65. Geburtstag gewidmet.
Dr R Ziesche
Abteilung Innere Medizin IV Universität Wien
Währinger Gürtel 18 - 20 1090 Wien Österreich
